Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi is running a global registry called “Atopic ...
Eczema, a chronic inflammatory skin condition, significantly impacts patients’ quality of life through persistent itching and ...
Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...
Jonathan Silverberg, MD, PhD, MPH, of George Washington University School of Medicine and Health Sciences, explains the benefits of using Janus kinase (JAK) inhibitors to treat patients with atopic ...
TORONTO, Dec. 2, 2025 /CNW/ - LEO Pharma Inc., a global leader in dermatology, is pleased to announce the availability of Anzupgo® (delgocitinib cream) across Canada for adults living with moderate to ...
The MarketWatch News Department was not involved in the creation of this content. -- Anzupgo(R) (delgocitinib cream) is the first topical pan-Janus kinase (JAK) treatment to be specifically indicated ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback